US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
CN103030617A
(en)
*
|
2004-03-16 |
2013-04-10 |
贝林格尔.英格海姆国际有限公司 |
Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
US7393836B2
(en)
*
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
JP2008508213A
(en)
*
|
2004-07-27 |
2008-03-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
D-glucopyranosyl-phenyl-substituted cyclics, pharmaceuticals containing such compounds, their use and methods for their production
|
DE102004048388A1
(en)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-pyranosyl-substituted phenyls, pharmaceutical compositions containing them, their use and processes for their preparation
|
DE102004054054A1
(en)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
|
EP1828216B1
(en)
*
|
2004-12-16 |
2008-09-10 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
CA2595257A1
(en)
|
2005-02-23 |
2006-08-31 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
|
ATE453656T1
(en)
*
|
2005-04-15 |
2010-01-15 |
Boehringer Ingelheim Int |
GLUCOPYRANOSYL-SUBSTITUTED (HETEROARYLOXY-BENZYL)-BENZENE DERIVATIVES AS SGLT INHIBITORS
|
UA91546C2
(en)
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
US7723309B2
(en)
*
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
US7772191B2
(en)
*
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
CA2616294A1
(en)
*
|
2005-07-27 |
2007-02-08 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
|
DE102005035891A1
(en)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
|
WO2007025943A2
(en)
*
|
2005-08-30 |
2007-03-08 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
AU2006289093A1
(en)
|
2005-09-08 |
2007-03-15 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
AR056195A1
(en)
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
PROCEDURES TO PREPARE DERIVATIVES OF (ETINIL-BENCIL) -BENZENE REPLACED GLUCOPYRANOSIL AND INTERMEDIATE COMPOUNDS OF THE SAME
|
JP2009531291A
(en)
|
2006-02-15 |
2009-09-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing these compounds, their use and methods of manufacture
|
ES2369016T3
(en)
*
|
2006-02-15 |
2011-11-24 |
Boehringer Ingelheim International Gmbh |
BENZONITRILE DERIVATIVES REPLACED BY GLUCOPIRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH TYPES OF COMPOUNDS, THEIR USE AND PROCEDURE FOR MANUFACTURING.
|
PE20080697A1
(en)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
BENZONITRILE DERIVATIVES SUBSTITUTED WITH GLUCOPYRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF THIS TYPE, THEIR USE AND PROCEDURE FOR THEIR MANUFACTURE
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
PE20080251A1
(en)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
USES OF DPP IV INHIBITORS
|
CN109503584A
(en)
|
2006-05-04 |
2019-03-22 |
勃林格殷格翰国际有限公司 |
Polymorphic
|
CN101490028B
(en)
*
|
2006-05-19 |
2013-02-06 |
大正制药株式会社 |
C-Phenyl polyol compound
|
US7803778B2
(en)
*
|
2006-05-23 |
2010-09-28 |
Theracos, Inc. |
Glucose transport inhibitors and methods of use
|
TWI403516B
(en)
|
2006-07-27 |
2013-08-01 |
Chugai Pharmaceutical Co Ltd |
To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
|
TWI432446B
(en)
|
2006-07-27 |
2014-04-01 |
Chugai Pharmaceutical Co Ltd |
Fused ring spiroketal derivative and use thereof as anti-diabetic drug
|
US8039441B2
(en)
|
2006-08-15 |
2011-10-18 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
|
US8956625B2
(en)
|
2006-09-07 |
2015-02-17 |
Glaxosmithkline Biologicals, S.A. |
Inactivated polio vaccines
|
EP2061442B1
(en)
|
2006-09-08 |
2016-08-31 |
Rhode Island Hospital |
Treatment, prevention, and reversal of alcohol-induced brain disease
|
US7858587B2
(en)
*
|
2006-09-21 |
2010-12-28 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture
|
TWI499414B
(en)
*
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
Inhibitors of sodium glucose co-transporter 2 and methods of their use
|
EP2072522A4
(en)
|
2006-10-13 |
2010-01-06 |
Chugai Pharmaceutical Co Ltd |
Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes
|
EP2086991A1
(en)
*
|
2006-10-27 |
2009-08-12 |
Boehringer Ingelheim International GmbH |
CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
|
EP2079753A1
(en)
*
|
2006-11-06 |
2009-07-22 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
|
WO2008055940A2
(en)
*
|
2006-11-09 |
2008-05-15 |
Boehringer Ingelheim International Gmbh |
Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
|
EP2105442A4
(en)
|
2006-12-21 |
2013-01-23 |
Astellas Pharma Inc |
Method for producing c-glycoside derivative and synthetic intermediate thereof
|
US7795228B2
(en)
*
|
2006-12-28 |
2010-09-14 |
Theracos, Inc. |
Spiroheterocyclic glycosides and methods of use
|
US20100081625A1
(en)
*
|
2007-01-26 |
2010-04-01 |
Boehringer Ingelheim International Gmbh |
Methods for preventing and treating neurodegenerative disorders
|
WO2008101939A1
(en)
*
|
2007-02-21 |
2008-08-28 |
Boehringer Ingelheim International Gmbh |
Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
WO2008101938A1
(en)
*
|
2007-02-21 |
2008-08-28 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
|
US7846945B2
(en)
*
|
2007-03-08 |
2010-12-07 |
Lexicon Pharmaceuticals, Inc. |
Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
|
ES2466672T3
(en)
*
|
2007-04-02 |
2014-06-10 |
Theracos, Inc. |
Benzyl glycoside derivatives and methods of use
|
CL2008002427A1
(en)
*
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus.
|
BRPI0815708B8
(en)
|
2007-08-23 |
2021-05-25 |
Theracos Sub Llc |
compound, prodrug ester, pharmaceutical composition, and, method of treating a disease or condition
|
MX2010002695A
(en)
*
|
2007-09-10 |
2010-04-01 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt.
|
US8648085B2
(en)
*
|
2007-11-30 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
CL2008003653A1
(en)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition.
|
ES2541141T3
(en)
*
|
2008-01-31 |
2015-07-16 |
Astellas Pharma Inc. |
Pharmaceutical composition for the treatment of fatty liver diseases
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
PE20091730A1
(en)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
FORMULATIONS INVOLVING A DPP4 INHIBITOR
|
EP2291189B1
(en)
|
2008-05-22 |
2014-10-01 |
AstraZeneca AB |
Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
|
CA2730734C
(en)
|
2008-07-15 |
2017-04-25 |
Theracos, Inc. |
Deuterated 2,3,4-trihydroxy-tetrahydropyranyl-benzylbenzene compounds having sodium glucose cotransporter inhibitory activity
|
KR20190016601A
(en)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
Treatment for diabetes in patients inappropriate for metformin therapy
|
UY32030A
(en)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
|
CN105237502A
(en)
*
|
2008-08-22 |
2016-01-13 |
泰拉科斯萨伯有限责任公司 |
Processes for the preparation of SGLT2 inhibitors
|
ME01285A
(en)
*
|
2008-08-28 |
2013-06-20 |
Pfizer |
Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
|
EA201100446A1
(en)
|
2008-09-08 |
2011-10-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
PYRAZOLOPYRIMIDINES AND THEIR APPLICATION FOR THE TREATMENT OF CNS DAMAGE
|
KR20110067096A
(en)
|
2008-09-10 |
2011-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
Combination Therapy to Treat Diabetes and Related Conditions
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
US9056850B2
(en)
*
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
EP2382216A1
(en)
|
2008-12-23 |
2011-11-02 |
Boehringer Ingelheim International GmbH |
Salt forms of organic compound
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
NZ594487A
(en)
*
|
2009-02-13 |
2013-11-29 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
GEP20146120B
(en)
*
|
2009-02-13 |
2014-07-25 |
Boehringer Ingelheim Int |
Sglt-2 inhibitor for treating type i diabetes mellitus, type ii diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
UY32427A
(en)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME
|
NZ594024A
(en)
*
|
2009-02-13 |
2013-08-30 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
|
EP2414363B1
(en)
*
|
2009-03-31 |
2014-01-08 |
Boehringer Ingelheim International GmbH |
1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
WO2011003976A1
(en)
|
2009-07-10 |
2011-01-13 |
Janssen Pharmaceutica Nv |
CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL] BENZENE
|
AR077859A1
(en)
*
|
2009-08-12 |
2011-09-28 |
Boehringer Ingelheim Int |
COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
|
DK2480559T3
(en)
|
2009-09-21 |
2013-08-05 |
Gilead Sciences Inc |
METHODS AND INTERMEDIATES FOR THE PREPARATION OF 1'-CYANO-CARBANUCLEOSIDE ANALOGS
|
KR101813025B1
(en)
|
2009-09-30 |
2017-12-28 |
베링거 인겔하임 인터내셔날 게엠베하 |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
|
JP5736377B2
(en)
|
2009-09-30 |
2015-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Process for the preparation of the crystalline form of 1-chloro-4- (β-D-glucopyranos-1-yl) -2- [4-((S) -tetrahydrofuran-3-yloxy) benzyl] benzene
|
UY32919A
(en)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Pharmaceutical composition, pharmaceutical dosage form, procedure for its preparation, methods for its treatment and its uses
|
MX340214B
(en)
*
|
2009-10-14 |
2016-06-30 |
Janssen Pharmaceutica Nv * |
Process for the preparation of compounds useful as inhibitors of sglt2.
|
PL2496583T3
(en)
|
2009-11-02 |
2015-04-30 |
Pfizer |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
KR20120107080A
(en)
|
2009-11-27 |
2012-09-28 |
베링거 인겔하임 인터내셔날 게엠베하 |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
EP2368552A1
(en)
|
2010-03-25 |
2011-09-28 |
Boehringer Ingelheim Vetmedica GmbH |
1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
|
WO2011120923A1
(en)
|
2010-03-30 |
2011-10-06 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
CA2795513A1
(en)
|
2010-04-06 |
2011-10-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
EA033415B1
(en)
|
2010-05-05 |
2019-10-31 |
Boehringer Ingelheim Int |
Methods for treating obesity, use of dpp-4 inhibitor in these methods and method for treating patients suffering from type 2 diabetes mellitus
|
HUE029853T2
(en)
|
2010-05-11 |
2017-04-28 |
Janssen Pharmaceutica Nv |
Pharmaceutical formulations containing 1- (beta-D-Glucopyranosyl) -2-thienylmethylbenzene derivatives as SGLT inhibitors
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
KR20130093012A
(en)
|
2010-06-24 |
2013-08-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
Diabetes therapy
|
PE20171155A1
(en)
|
2010-07-22 |
2017-08-16 |
Gilead Sciences Inc |
METHODS AND COMPOUNDS TO TREAT VIRAL PARAMYXOVIRIDAE INFECTIONS
|
PE20130602A1
(en)
|
2010-08-12 |
2013-05-25 |
Boehringer Ingelheim Int |
6-CYCLOALKYL-1,5-DIHYDRO-PYRAZOLE (3,4-D) PYRIMIDIN-4-ONAS DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS
|
WO2012025857A1
(en)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
|
US10894787B2
(en)
|
2010-09-22 |
2021-01-19 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
CN102453026A
(en)
*
|
2010-10-27 |
2012-05-16 |
上海艾力斯医药科技有限公司 |
C-aryl glucoside derivative, preparation method and application thereof
|
AU2011325286B2
(en)
|
2010-11-02 |
2015-04-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations for the treatment of metabolic disorders
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
US8980829B2
(en)
|
2011-02-18 |
2015-03-17 |
Shanghai Yingli Science And Technology Co., Ltd |
Aryl glycoside compound, preparation method and use thereof
|
UY33937A
(en)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
|
US20140018371A1
(en)
|
2011-04-01 |
2014-01-16 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
JP5973551B2
(en)
|
2011-04-13 |
2016-08-23 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Process for preparing compounds useful as inhibitors of SGLT2
|
US20140066369A1
(en)
|
2011-04-19 |
2014-03-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
US20140038889A1
(en)
|
2011-04-22 |
2014-02-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
US20140051714A1
(en)
|
2011-04-22 |
2014-02-20 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
TWI542596B
(en)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
(2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxyl L-proline and citric acid cocrystals of methyl)tetrahydro-2H-piperan-3,4,5-triol
|
JP5835598B2
(en)
*
|
2011-06-03 |
2015-12-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
SGLT-2 inhibitor for treating metabolic disorders in patients being treated with neuroleptics
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
CN102875503B
(en)
*
|
2011-06-25 |
2016-05-25 |
山东轩竹医药科技有限公司 |
C-glycosides derivatives
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
PL3517539T3
(en)
|
2011-07-15 |
2023-04-24 |
Boehringer Ingelheim International Gmbh |
Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
RU2500407C2
(en)
*
|
2012-02-20 |
2013-12-10 |
Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации |
Diuretic agent
|
RU2517091C2
(en)
*
|
2012-02-20 |
2014-05-27 |
Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации) |
Medication, possessing diuretic action
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
WO2013167554A1
(en)
|
2012-05-09 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations for the treatment of metabolic disorders
|
US20130303462A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
|
EP2849754B1
(en)
|
2012-05-14 |
2022-09-14 |
Boehringer Ingelheim International GmbH |
Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US9145434B2
(en)
*
|
2012-07-26 |
2015-09-29 |
Boehringer Ingelheim International Gmbh |
Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
CN103864737B
(en)
*
|
2012-12-17 |
2016-08-17 |
天津药物研究院 |
Phenyl C-glucoside derivative containing deoxyglucose structure and its production and use
|
CN103910769B
(en)
|
2012-12-31 |
2018-10-02 |
上海璎黎药业有限公司 |
The compound of glucosan derivative and proline, crystal, preparation method and application
|
ES2969245T3
(en)
|
2013-03-14 |
2024-05-17 |
Msd Int Gmbh |
Crystal forms and methods for preparing SGLT2 inhibitors
|
EP4245765A3
(en)
|
2013-04-04 |
2024-03-20 |
Boehringer Ingelheim Vetmedica GmbH |
Treatment of metabolic disorders in equine animals
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
HK1213818A1
(en)
|
2013-04-05 |
2016-07-15 |
勃林格殷格翰国际有限公司 |
Therapeutic uses of empagliflozin
|
HUE041709T2
(en)
|
2013-04-05 |
2019-05-28 |
Boehringer Ingelheim Int |
Therapeutic uses of empagliflozin
|
HK1215378A1
(en)
|
2013-04-18 |
2016-08-26 |
勃林格殷格翰国际有限公司 |
Pharmaceutical composition, methods for treating and uses thereof
|
CN104250272B
(en)
*
|
2013-06-27 |
2018-10-09 |
上海方楠生物科技有限公司 |
A method of it is prepared using microreactor and arranges net class pharmaceutical intermediate
|
WO2015051484A1
(en)
|
2013-10-12 |
2015-04-16 |
Theracos, Inc. |
Preparation of hydroxy-benzylbenzene derivatives
|
WO2015063726A1
(en)
*
|
2013-10-31 |
2015-05-07 |
Ranbaxy Laboratories Limited |
Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
|
DK3862003T3
(en)
|
2013-12-17 |
2024-01-29 |
Boehringer Ingelheim Vetmedica Gmbh |
SGLT2 INHIBITORS FOR USE IN THE TREATMENT OF A FELINE METABOLISM DISORDER
|
US9902751B2
(en)
|
2013-12-30 |
2018-02-27 |
Mylan Laboratories Limited |
Process for the preparation of empagliflozin
|
CN106349201B
(en)
*
|
2014-01-03 |
2018-09-18 |
山东轩竹医药科技有限公司 |
The C- glycosides derivatives of optically pure benzyl -4- chlorphenyls
|
ES2593050T3
(en)
|
2014-01-03 |
2016-12-05 |
Xuanzhu Pharma Co., Ltd. |
Optically pure benzyl-4-chlorophenyl-C-glycoside derivatives as inhibitors of SGLT (diabetes mellitus)
|
US9315438B2
(en)
|
2014-01-03 |
2016-04-19 |
Xuanzhu Pharma Co., Ltd |
Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
|
CN103739581B
(en)
*
|
2014-01-23 |
2016-11-23 |
中国药科大学 |
C-aryl glucoside SGLT2 inhibitor
|
DK3485890T3
(en)
*
|
2014-01-23 |
2023-08-21 |
Boehringer Ingelheim Vetmedica Gmbh |
SGLT2 INHIBITORS FOR THE TREATMENT OF CANINE METABOLISM DISORDERS
|
CN104861002A
(en)
*
|
2014-02-26 |
2015-08-26 |
天津药物研究院 |
3,6-anhydroglucose structure-containing phenyl C-glucoside derivatives and their preparation method and use
|
ES2950384T3
(en)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Medical use of a DPP-4 inhibitor
|
DK3125882T3
(en)
|
2014-04-01 |
2020-06-29 |
Boehringer Ingelheim Vetmedica Gmbh |
TREATMENT OF METABOLIC DISORDERS IN ANIMAL ANIMALS
|
CN105001213B
(en)
*
|
2014-04-14 |
2020-08-28 |
上海迪诺医药科技有限公司 |
C-aryl glycoside derivative, pharmaceutical composition, preparation method and application thereof
|
EP3197429B1
(en)
|
2014-09-25 |
2024-05-22 |
Boehringer Ingelheim Vetmedica GmbH |
Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
|
TWI740546B
(en)
|
2014-10-29 |
2021-09-21 |
美商基利科學股份有限公司 |
Methods for the preparation of ribosides
|
DE102014018230B4
(en)
*
|
2014-12-04 |
2016-10-27 |
Mann + Hummel Gmbh |
Accumulator arrangement for a vehicle
|
WO2016128995A1
(en)
*
|
2015-02-09 |
2016-08-18 |
Indoco Remedies Limited |
Process for the preparation of sglt inhibitor compounds
|
CZ2015110A3
(en)
|
2015-02-18 |
2016-08-31 |
Zentiva, K.S. |
Empagliflozin solid forms
|
CN107683135A
(en)
|
2015-03-09 |
2018-02-09 |
因特克林医疗有限公司 |
Method for treating NASH disease and/or lipodystrophia
|
CZ2015279A3
(en)
|
2015-04-24 |
2016-11-02 |
Zentiva, K.S. |
Amorphous empagliflozin solid forms
|
JP6561136B2
(en)
|
2015-04-30 |
2019-08-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Method for treating or ameliorating erectile dysfunction and pharmaceutical composition comprising SGLT2 inhibitor
|
CN106336403A
(en)
*
|
2015-07-14 |
2017-01-18 |
江苏豪森药业集团有限公司 |
Industrial preparation method for empagliflozin
|
CA2996458C
(en)
|
2015-08-27 |
2024-04-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Liquid pharmaceutical compositions comprising sglt-2 inhibitors
|
WO2017046730A1
(en)
|
2015-09-15 |
2017-03-23 |
Laurus Labs Private Limited |
Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
US10251904B2
(en)
|
2015-09-16 |
2019-04-09 |
Gilead Sciences, Inc. |
Methods for treating arenaviridae and coronaviridae virus infections
|
JP2018530592A
(en)
|
2015-10-15 |
2018-10-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
SGLT-2 inhibitor for use in the treatment of metabolic myopathy
|
RU2614142C1
(en)
*
|
2016-01-14 |
2017-03-23 |
Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский политехнический университет" |
Method for production of meta-chlorobenzhydrylamine - semi-product in synthesis of anticonvulsant preparation galodif
|
WO2017130217A1
(en)
*
|
2016-01-27 |
2017-08-03 |
Msn Laboratories Private Limited |
The present invention relates to process for the preparation of d-glucitol, 1,5- anhydro-1-c-[4-chloro-3-[[4-[[(3s)-tetrahydro-3-furanyl] oxy]phenyl] methyl]phenyl]-, (1s) and its crystalline forms thereof.
|
WO2017141202A1
(en)
*
|
2016-02-17 |
2017-08-24 |
Lupin Limited |
Complex of sglt2 inhibitor and process for preparation thereof
|
AU2017276758A1
(en)
|
2016-06-10 |
2018-11-08 |
Boehringer Ingelheim International Gmbh |
Combinations of Linagliptin and metformin
|
CN107641139A
(en)
*
|
2016-07-22 |
2018-01-30 |
江苏豪森药业集团有限公司 |
Crystal formation of Dapagliflozin intermediate and preparation method thereof
|
SI3526229T1
(en)
|
2016-10-13 |
2021-08-31 |
Boehringer Ingelheim International Gmbh |
Process for preparing glucopyranosyl-substituted benzyl-benzene derivatives
|
US20210212968A1
(en)
|
2016-10-19 |
2021-07-15 |
Boehringer Ingelheim International Gmbh |
Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
|
NZ751816A
(en)
|
2016-11-10 |
2025-05-30 |
Boehringer Ingelheim Int |
Pharmaceutical composition, methods for treating and uses thereof
|
CN108285439B
(en)
*
|
2017-01-09 |
2023-05-02 |
江苏天士力帝益药业有限公司 |
Carbonoside sodium glucose transport protein body 2 inhibitor
|
WO2018163194A1
(en)
*
|
2017-03-10 |
2018-09-13 |
Msn Laboratories Private Limited, R&D Center |
A process for the preparation of d-glucitol, 1,5-anhydro-1-c-[4-chloro-3-[[4- [[(3s)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, ( 1 s)
|
AU2018235754B2
(en)
|
2017-03-14 |
2021-04-08 |
Gilead Sciences, Inc. |
Methods of treating feline coronavirus infections
|
WO2018187350A1
(en)
|
2017-04-03 |
2018-10-11 |
Coherus Biosciences Inc. |
PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
|
EP3618929B1
(en)
|
2017-05-01 |
2022-12-07 |
Gilead Sciences, Inc. |
A crystalline form of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
WO2018207111A1
(en)
|
2017-05-09 |
2018-11-15 |
Piramal Enterprises Limited |
A process for the preparation of sglt2 inhibitors and intermediates thereof
|
US11046676B2
(en)
|
2017-06-05 |
2021-06-29 |
Laurus Labs Limited |
Process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof
|
CN107163092B
(en)
*
|
2017-06-13 |
2020-05-19 |
杭州科巢生物科技有限公司 |
Preparation method of SGLT-2 diabetes inhibitor and intermediate thereof
|
US11753431B2
(en)
*
|
2017-07-04 |
2023-09-12 |
Intocell, Inc. |
Compounds comprising cleavable linker and uses thereof
|
US10675296B2
(en)
|
2017-07-11 |
2020-06-09 |
Gilead Sciences, Inc. |
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
|
CA3083327A1
(en)
|
2017-11-30 |
2019-06-06 |
Idorsia Pharmaceuticals Ltd |
Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
|
JP2021515767A
(en)
|
2018-03-07 |
2021-06-24 |
バイエル・アクチエンゲゼルシヤフト |
Identification and use of ERK5 inhibitors
|
US20210113561A1
(en)
|
2018-04-17 |
2021-04-22 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
CZ2018188A3
(en)
|
2018-04-18 |
2019-10-30 |
Zentiva, K.S. |
Amorphous empagliflozin particles, process for preparing them and pharmaceutical preparation
|
CN108610385A
(en)
*
|
2018-04-23 |
2018-10-02 |
中国科学院成都生物研究所 |
A kind of medicinal usage of white 1 inhibitor of sodium glucose co-transporter 2
|
CN110117300A
(en)
*
|
2018-04-23 |
2019-08-13 |
中国科学院成都生物研究所 |
Medicinal usage comprising white 1 inhibitor of sodium glucose co-transporter 2
|
KR102204439B1
(en)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Pharmaceutical Composition comprising SGLT-2 inhibitor and DPP-IV inhibitor
|
CN108774275A
(en)
*
|
2018-07-16 |
2018-11-09 |
西北大学 |
The method of the full acetyl group-α-O- benzyls sugar of one-step synthesis
|
PE20210644A1
(en)
|
2018-07-19 |
2021-03-23 |
Astrazeneca Ab |
METHODS OF TREATMENT OF HFpEF USING DAPAGLIFLOZIN AND COMPOSITIONS INCLUDING THE SAME
|
EP3826642B8
(en)
|
2018-07-25 |
2025-06-11 |
Boehringer Ingelheim International GmbH |
Empagliflozin for use in treating alport syndrome
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
TW202024046A
(en)
*
|
2018-09-06 |
2020-07-01 |
日商德山股份有限公司 |
Production method for [beta]-C-aryl glycoside derivative
|
WO2020084560A1
(en)
*
|
2018-10-26 |
2020-04-30 |
Janssen Pharmaceutica Nv |
Glucopyranose derivatives useful as sglt2 inhibitors
|
DK3873600T5
(en)
|
2018-10-29 |
2024-03-18 |
Boehringer Ingelheim Int |
PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
|
US12213970B2
(en)
|
2018-10-29 |
2025-02-04 |
Boehringer Ingelheim International Gmbh |
Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
|
WO2020242253A1
(en)
*
|
2019-05-30 |
2020-12-03 |
동아에스티 주식회사 |
Novel empagliflozin derivative which is sglt-2 inhibitor
|
CN112047915B
(en)
*
|
2019-06-05 |
2023-02-17 |
北京惠之衡生物科技有限公司 |
Novel preparation process of C-glycoside derivatives
|
AU2020310274B2
(en)
*
|
2019-07-05 |
2022-09-29 |
Shandong Danhong Pharmaceutical Co., Ltd. |
Crystal form of SGLT inhibitor and application thereof
|
US12378277B2
(en)
|
2019-07-26 |
2025-08-05 |
Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. |
SGLTS/DPP4 inhibitor and application thereof
|
WO2021105152A1
(en)
|
2019-11-28 |
2021-06-03 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors in the drying-off of non-human mammals
|
WO2021123165A1
(en)
|
2019-12-19 |
2021-06-24 |
Krka, D.D., Novo Mesto |
Dosage form comprising amorphous solid solution of empagliflozin with polymer
|
KR102111248B1
(en)
|
2019-12-30 |
2020-05-14 |
유니셀랩 주식회사 |
New Empagliflozin cocrystal
|
US11660307B2
(en)
|
2020-01-27 |
2023-05-30 |
Gilead Sciences, Inc. |
Methods for treating SARS CoV-2 infections
|
CA3167531A1
(en)
|
2020-02-17 |
2021-08-26 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
|
MX2022010748A
(en)
|
2020-03-06 |
2022-09-23 |
Vertex Pharma |
Methods of treating apol-1 dependent focal segmental glomerulosclerosis.
|
EP4118085A2
(en)
|
2020-03-12 |
2023-01-18 |
Gilead Sciences, Inc. |
Methods of preparing 1'-cyano nucleosides
|
KR102207319B1
(en)
|
2020-03-23 |
2021-01-25 |
유니셀랩 주식회사 |
New Empagliflozin cocrystal
|
JP7482250B2
(en)
|
2020-04-06 |
2024-05-13 |
ギリアード サイエンシーズ, インコーポレイテッド |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
KR102150825B1
(en)
|
2020-04-06 |
2020-09-03 |
유니셀랩 주식회사 |
Novel sglt-2 inhibitors cocrystal
|
EP4132536A1
(en)
|
2020-04-07 |
2023-02-15 |
Boehringer Ingelheim International GmbH |
Methods for the treatment of headache disorders
|
EP4138826A1
(en)
|
2020-04-22 |
2023-03-01 |
Bayer Aktiengesellschaft |
Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
|
AU2021281351A1
(en)
|
2020-05-29 |
2023-01-19 |
Gilead Sciences, Inc. |
Remdesivir treatment methods
|
WO2021250565A1
(en)
*
|
2020-06-10 |
2021-12-16 |
Hikal Limited |
An improved process for preparation of empagliflozin and its crystalline polymorph
|
CN115996928A
(en)
|
2020-06-24 |
2023-04-21 |
吉利德科学公司 |
1' -cyanonucleoside analogs and uses thereof
|
US11786540B2
(en)
*
|
2020-07-10 |
2023-10-17 |
Rosalind Franklin University Of Medicine And Science |
Gliflozins and a method for their delivery during resuscitation from cardiac arrest to improve survival outcomes
|
US12409186B2
(en)
|
2020-07-27 |
2025-09-09 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
DK4204421T3
(en)
|
2020-08-27 |
2024-05-27 |
Gilead Sciences Inc |
Compounds and methods for treating viral infections
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
KR20220068805A
(en)
|
2020-11-19 |
2022-05-26 |
한미약품 주식회사 |
Novel glucose derivatives
|
EP4023644A1
(en)
|
2020-12-30 |
2022-07-06 |
Zaklady Farmaceutyczne Polpharma SA |
Process for the preparation of a pharmaceutical agent
|
WO2022160737A1
(en)
*
|
2021-01-26 |
2022-08-04 |
东宝紫星(杭州)生物医药有限公司 |
Crystal form of tetrahydropyran ring compound and preparation method therefor
|
AU2022251165A1
(en)
|
2021-04-01 |
2023-11-09 |
Astrazeneca Uk Limited |
Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
|
MX2024001185A
(en)
|
2021-07-28 |
2024-02-27 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals.
|
WO2023006745A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
US20240398845A1
(en)
|
2021-07-28 |
2024-12-05 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
|
CN113773194B
(en)
|
2021-08-16 |
2023-05-02 |
浙江奥翔药业股份有限公司 |
Preparation method of 5-bromo-2-chloro-benzoic acid as synthesis raw material of hypoglycemic agent
|
CN119997931A
(en)
|
2021-12-30 |
2025-05-13 |
纽阿姆斯特丹制药公司 |
Obicetrapib and SGLT2 inhibitor combination
|
JP2025503136A
(en)
|
2022-01-26 |
2025-01-30 |
アストラゼネカ・アクチエボラーグ |
Dapagliflozin for use in treating prediabetes or reducing the risk of developing type 2 diabetes
|
EP4320128A1
(en)
|
2022-03-02 |
2024-02-14 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
WO2023213715A1
(en)
|
2022-05-04 |
2023-11-09 |
Société des Produits Nestlé S.A. |
Ampk activator (cbda) and sglt2 inhibitor for metabolic health
|
EP4524138A4
(en)
|
2022-05-12 |
2025-09-03 |
Zhejiang Huahai Pharm Co Ltd |
Process for preparing a glucopyranosyl-containing compound
|
CN119110722A
(en)
|
2022-05-25 |
2024-12-10 |
勃林格殷格翰动物保健有限公司 |
Aqueous pharmaceutical composition containing SGLT-2 inhibitors
|
WO2024033287A1
(en)
|
2022-08-12 |
2024-02-15 |
Société des Produits Nestlé S.A. |
Hydroxycholest-5-ene glycosides as inhibitors of sglt2
|
WO2024033288A1
(en)
|
2022-08-12 |
2024-02-15 |
Société des Produits Nestlé S.A. |
Salicin derivatives as inhibitors of sglt2
|
CN119654142A
(en)
|
2022-08-18 |
2025-03-18 |
雀巢产品有限公司 |
Methylated phloretin analogs as inhibitors of SGLT2
|
WO2024056498A1
(en)
|
2022-09-12 |
2024-03-21 |
Société des Produits Nestlé S.A. |
Oxindole alkaloid derivatives as inhibitors of sglt2
|
WO2024068511A1
(en)
|
2022-09-28 |
2024-04-04 |
Société des Produits Nestlé S.A. |
Diterpenoid derivatives as inhibitors of sglt2
|
EP4378455A1
(en)
|
2022-11-29 |
2024-06-05 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A pharmaceutical formulation comprising empagliflozin
|
CN115772163B
(en)
*
|
2022-12-09 |
2025-07-22 |
中国科学院成都生物研究所 |
Indole glycoside compound and pyrrole glycoside compound, and synthesis method and application thereof
|
EP4420658A1
(en)
|
2023-02-24 |
2024-08-28 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A film coated tablet comprising empagliflozin
|
US20240307628A1
(en)
|
2023-03-06 |
2024-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
|
EP4442254A1
(en)
|
2023-04-04 |
2024-10-09 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Film coated tablets comprising empagliflozin
|
EP4442253A1
(en)
|
2023-04-04 |
2024-10-09 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A film coated tablet comprising empagliflozin and surfactant
|
EP4442252A1
(en)
|
2023-04-04 |
2024-10-09 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A tablet formulation of a solid dispersion comprising empagliflozin
|
WO2024226537A1
(en)
|
2023-04-24 |
2024-10-31 |
Newamsterdam Pharma B.V. |
Amorphous obicetrapib and sglt2 inhibitor combination
|
US20240390317A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
|
US20240390332A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan
|
KR20250007816A
(en)
|
2023-07-06 |
2025-01-14 |
주식회사 경보제약 |
Novel Crystalline form of Empagliflozin 2L-proline and methods of preparing thereof
|
TW202525278A
(en)
|
2023-12-15 |
2025-07-01 |
愛爾蘭商阿斯特捷利康愛爾蘭有限公司 |
Methods of treating chronic kidney disease and hypertension
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|
WO2025191117A1
(en)
|
2024-03-15 |
2025-09-18 |
Inventiva |
Prevention of blood disorders in patient treated with a ppar agonist
|